The government has disbursed Rs 1,596 crore under Production-Linked Incentive (PLI) schemes for six sectors, including electronics and pharma, during the April-September this fiscal, an official said. The government in
Shares of Cipla dropped 3.55 percent, trading at Rs 1,450 on the BSE on Tuesday as investors await the company’s Q2 FY25 results scheduled for release today, October 29, 2024.
如何提升線上差價合 差價合約交易讓交易者推測各種資產的價格變動，包括股票、指數、外匯對和商品。這種類型的交易使用槓桿，放大潛在的收益和損失。為了提高您的線上差價合約交易技能，練習和持續學習非常重要。您可以透過在您選擇的經紀商開設模擬帳戶並使用虛擬資金進行練習來做到這一點。 差價合約是一種無需擁有標的資產即可推測價格變動的方式。在這種類型的交易中，您可以在平台上建立多頭或空頭頭寸，您的利潤或損失取決於買入價和賣出價之間的差額。差價合約交易提供了新水準的靈活性和增加財富的機會，同時也培養新的分析和決策技能。它還可以透過提供比傳統投資方法更高的回報來實現財務自由。 差價合約交易最重要的第一步是選擇信譽良好的經紀商並開設模擬帳戶。這使您可以練習並熟悉交易軟體和工具，同時在無風險的環境中測試您的策略。一旦找到合適的經紀商，制定全面的交易計畫就很重要。這將幫助您保持專注和紀律，並確保您的交易決策是基於客觀的研究和分析，而不是情緒衝動。 在線cfd交易 正確的線上經紀商可以對您的交易表現產生巨大的影響。您應該尋找一家提供有競爭力的點差、低佣金率和透明的定價結構的差價合約經紀商。選擇提供延長交易時間和良好客戶支援的經紀商也很重要。 如何提升線上差價合約交易技能？ 您還應該尋找提供廣泛金融工具的經紀商。這包括外匯、股票、指數和商品。一些經紀商甚至允許交易者交易加密貨幣。最後，一定要選擇提供各種教育資源的經紀人，例如隨選視訊和部落格。 交易差價合約指數時，制定全面的交易計劃並限制槓桿至關重要。過高的槓桿可能會導致過度交易和追逐損失，因此您應該始終控制風險。此外，保留交易日誌並定期分析您過去的交易也很重要。這將幫助您確定需要改進的模式和領域。 差價合約交易是一種流行的衍生性商品交易形式，允許交易者在不擁有標的資產的情況下推測貨幣、商品和指數等不同金融工具的價格上漲或下跌。這是利用槓桿和低保證金要求參與全球市場的好方法。對於任何差價合約交易者來說，制定交易計畫都是至關重要的第一步。它將幫助您設定切合實際的回報期望，並防止衝動決策，從而導致代價高昂的錯誤。 使用各種頭寸調整技術來限制您的風險敞口也很重要。這些策略將幫助您確定在任何給定時間可以進入和退出的頭寸數量，以最大限度地降低風險。此外，了解風險回報率如何適合您的個人交易風格也至關重要。例如，一些交易者更喜歡風險回報率，該比率傾向於回報最大化利潤。而其他人則喜歡更平衡的風險回報率，以最大限度地減少損失。 差價合約交易可能有風險，因此有效管理風險非常重要。這包括制定可靠的交易計劃、設定止損單以及分散倉位。它還需要監控市場狀況，包括央行公告和經濟數據。交易者也應該注意可能影響價格的地緣政治事件。 降低風險的另一種方法是使用 eToro 或 ZuluTrade 等社交交易平台。這些平台允許交易者自動或手動複製經驗豐富的交易者的交易。這是了解更多有關差價合約交易並避免犯下代價高昂的錯誤的好方法。 槓桿是一個強大的工具，可以放大您的利潤，但也可以放大您的損失。此外，槓桿是經紀商為您提供啟動交易的一種信用形式。因此，了解保證金如何運作至關重要。例如，如果您的交易走勢對您不利，經紀商將要求您存入額外資金以彌補您的潛在損失。
Sun Pharmaceuticals Industries stocks gained on Tuesday on positive July-September quarter estimates. The scrip quoted Rs 1034 apiece on NSE, up 1 per cent, in afternoon session. The drug maker also
World-leading healthcare specialists Bravo Pharma have officially entered a strategic partnership with the region’s pioneering AI-powered healthcare company G42 Healthcare. In addition to this partnership, Bravo Pharma has also organized
Shares of Cipla surged more than 6 per cent in morning trade on Friday to hit a fresh 52-week high amid the buzz over one of largest global private equity
Torrent Pharmaceuticals Ltd shares registered a new 52-week high of Rs 2,089.85 per piece on the BSE on Tuesday after the company reported a rise in net profit and revenue
Pharma major Cipla Ltd will acquire the cosmetics and personal care distribution and marketing business of Ivia Beaute Pvt Ltd, including the latter’s brands Astaberry, Ikin and Bhimsaini, on a
Natco Pharma failed to maintain cleanliness, sterilise equipment and utensils at appropriate intervals at its Telangana-based plant, as per the US health regulator. In the warning letter to the company,
Balaxi Pharmaceuticals Limited has announced global expansion. In an exchange filing, the company shared details about strategic hospital partnerships in Angola and securing tender business in Latin America. The company said
India is set to see significant employment growth in the first half of the current fiscal year (FY25) across key industries, led by healthcare, pharma, automotive, manufacturing, engineering and infrastructure
Pharma company Remedium Lifecare has entered into a strategic agreement with Angel Partners, Ltd., UK, to acquire technology for manufacturing lithium carbonate in India. The company has also signed an
Sigachi Industries has unveiled two new product lines – PureCoat and UltraMod – which are innovative pharmaceutical film coatings and polymer blends. “These cutting-edge solutions are poised to transform the
Today, a brief rundown of news from Takeda and the Food and Drug Administration, as well as updates from Insmed, J.P. Morgan and Bristol Myers Squibb that you may have
Dive Brief: Telix, an Australia-based developer of radiopharmaceutical drugs for cancer, has canceled plans to raise roughly $200 million via an initial public offering on the Nasdaq stock exchange. The
AbbVie is securing its place in an emerging gastrointestinal disease drug field, paying China-based FutureGen Biopharmaceutical $150 million in immediate and near-term fees for rights to an antibody drug targeting
The Supreme Court on Thursday unanimously ruled an anti-abortion group contesting the Food and Drug Administration’s approval of the abortion pill mifepristone does not have a legal basis to sue,
Precision immunology has emerged as one of the hottest fields in drugmaking over the past several years, spurred by new ways to make more potent drugs that don’t trigger as
Pfizer’s experimental gene therapy for Duchenne muscular dystrophy didn’t improve the motor function of young boys enrolled in a late-stage trial meant to provide a decisive verdict on the treatment’s
Dive Brief: The Food and Drug Administration on Monday cleared a new treatment option for the rare liver disease primary biliary cholangitis, granting an accelerated approval to Ipsen’s drug Iqirvo.
Approval of Eli Lilly’s experimental Alzheimer’s disease drug donanemab would help drive sales of Eisai and Biogen’s rival medicine Leqembi, analysts wrote after a Food and Drug Administration panel on
Dive Brief: Moderna on Monday said a combination flu and COVID-19 shot it’s developing met the goal of a late-stage study, eliciting higher immune responses to the two viruses than
An experimental and closely watched medicine for Alzheimer’s disease is one step closer to approval, after receiving support from a panel of experts who advise the Food and Drug Administration.
As healthcare moves toward the shared goal of improving patient care more economically, stakeholders across the healthcare ecosystem are increasingly aligned with the principles of value-based care. Value-based care is
Dive Brief: Seres Therapeutics plans to sell all the rights to its microbiome pill to Nestlé Health Science as it struggles to fund operations. Under a nonbinding memorandum of understanding
A group of advisers to the Food and Drug Administration on Wednesday unanimously recommended that COVID-19 vaccines be updated to cover coronavirus strains with a family known as JN.1 ahead
After a turbulent few years, 2024 has given the biotechnology industry some signs of a return to normalcy. For one, venture investment appears to have stabilized at levels seen prior
Today, several brief updates from BioPharma Dive Reporter Gwendolyn Wu, who spent this week attending BIO’s annual meeting in San Diego, as well as notes on Geron, AbbVie and Deerfield
Long dismissed by top scientists and drug regulators, the use of psychedelics to treat mental health conditions has finally gained momentum over the last several years. But some proponents believe
Dive Brief: Expert advisers to the Food and Drug Administration will need to weigh whether Eli Lilly’s experimental Alzheimer’s disease drug donanemab is widely effective or should be restricted only
Listen to the article 2 min This audio is auto-generated. Please let us know if you have feedback. British drugmaker GSK is investing further in nucleic acid drug development, reaching
Dive Brief: Anat Ashkenazi will leave Eli Lilly’s executive suite at the end of July to become CFO and senior vice president of Google and Alphabet, the companies said Wednesday.
Today, a brief rundown of news from Eli Lilly, Cytokinetics and AbbVie, as well as updates from Gilead and the National Institutes of Health that you may have missed from
Dive Brief: Illumina’s board of directors has approved a spinoff of Grail, targeting June 24 as the date the cancer blood test maker will regain its independence. Illumina agreed to
Medical experts who advise the Food and Drug Administration are not convinced MDMA is ready for general use to help treat post-traumatic stress disorder, recommending at a meeting Tuesday the
Dive Brief: An experimental GLP-1 pill helped people with obesity lose significantly more weight than a placebo over three months, according to summary results revealed by developer Structure Therapeutics Monday.
BioPharma Dive is testing out a new format rounding up smaller updates from around the industry. Have thoughts on what could make this type of story better? Drop us a
Liquid biopsy has emerged as a revolutionary tool for clinical trials, offering cellular and cell-free methods that provide valuable insights into disease progression and treatment response. Circulating tumor cells (CTCs)
Two years ago, a drug called Enhertu changed the way doctors thought about treating an aggressive form of breast cancer, making it important to know not only whether their patients’
An accelerated approval for Gilead Sciences’ cancer drug Trodelvy could be in question after the company disclosed Thursday afternoon that a confirmatory trial failed to meet its main objective. In the
The Food and Drug Administration on Friday approved a third vaccine for respiratory syncytial virus, clearing a shot from biotechnology company Moderna one year after granting a green light to
BioPharma Dive is testing out a new format rounding up smaller updates from around the industry. Have thoughts on what could make this type of story better? Drop us a
Food and Drug Administration scientists have reservations about a potential new treatment for post-traumatic stress disorder that’s currently up for approval. Developed by an unusual company called Lykos Therapeutics, the
Otsuka America, a subsidiary of the Japanese drug and device maker, this month launched a new company focused on digital health. The firm, called Otsuka Precision Health, will roll out
Dive Brief: Immunovant told investors Wednesday that it’s shifting resources to focus on a less advanced experimental autoimmune disease treatment that appears more promising for future development. The company now
Dive Brief: Merck & Co. on Wednesday said it has agreed to buy privately held eye drug developer EyeBio for $1.3 billion in cash upfront and as much as $1.7
Dive Brief: Gameto, a biotechnology company developing new treatments for fertility, has raised $33 million in venture capital funding to advance technology it says could shorten in vitro fertilization cycles,
Dive Brief: Agios Pharmaceuticals has agreed to sell to Royalty Pharma rights to royalties on a brain cancer drug it invented and sold to Servier. Per deal terms announced Tuesday,
New Jersey-based drugmaker Insmed gained more than $3 billion in market value Tuesday after reporting clinical trial results for an experimental lung disease drug that impressed analysts. Data from the
Artificial intelligence (AI) has sparked a revolution in the pharmaceutical industry, reshaping the way we approach complex biological challenges. “From personalized medicine to unraveling the mysteries of our DNA, we’re
BioPharma Dive is testing out a new format rounding up smaller updates from around the industry. Have thoughts on what could make this type of story better? Drop us a
Dive Brief: Shares in Cytokinetics sank by about one-fifth Thursday on news of a funding deal the biotechnology company struck with Royalty Pharma, in which it traded away a stake
Dive Brief: German drugmaker Merck KGaA agreed to buy Mirus Bio for $600 million to build expertise in a critical part of viral vector-based gene therapy production. Merck KGaA is
Orna Therapeutics, a young biotechnology company focused on a flashy area of genetic research, is expanding through the acquisition of another well-funded startup. As its name suggests, the startup, ReNAgade
Eli Lilly plans to spend another $5.3 billion building production capacity for its popular obesity and diabetes drugs, responding to immense demand for the medicines with what it claims is
A top Food and Drug Administration official on Friday again advocated for the speedy approval of gene therapies for rare diseases. But he didn’t drop any clues on where the
BioPharma Dive is testing out a new format rounding up smaller updates from around the industry. Have thoughts on what could make this type of story better? Drop us a
An older form of hormone therapy taken to ease the symptoms of menopause could increase the risk of ovarian cancer, according to results released Thursday from two studies involving tens
Dive Brief: Biogen is scooping up a closely held immunology startup to bring more diversity to a pipeline best known for neurology products. Per deal terms, Biogen will pay $1.15
Pfizer, already in the midst of an aggressive effort to trim spending, on Wednesday disclosed new plans to cut at least $1.5 billion in additional costs over the next several
Eli Lilly is partnering with biotechnology company Aktis Oncology to develop radiopharmaceuticals for cancer, agreeing to a deal that will pay the startup $60 million upfront. Per terms announced Tuesday,
Dive Brief: AstraZeneca’s plan to reach $80 billion in sales by 2030 relies heavily on a slate of roughly one dozen cancer drugs it expects will become blockbuster sellers at
British biotechnology startup Pheon Therapeutics has raised another $120 million in venture funding, riding a wave of investor interest in the type of cancer medicines, known as antibody-drug conjugates, it
Forbion, a well-known backer of life sciences startups, is leading an investment round for a newly launched biotechnology company focused on diseases that affect nerve cells. The company, Progentos Therapeutics,
Dr. Zocca brings more than 20 years of experience in the biotechnology field and has founded and co-founded several biotech spinouts. Her focus on translational and clinical immune oncology has
Biogen and Ionis Pharmaceuticals are stopping development of an experimental drug for ALS following new clinical trial results that didn’t meet the companies’ expectations. The trial, which enrolled almost 100
Dive Brief: An experimental Roche drug helped people with obesity lose an average of nearly 19% of their body weight over six months, after adjusting for placebo, in an early-stage
A once-weekly form of insulin being developed by Eli Lilly proved just as effective at controlling blood sugar in adults with diabetes as commonly used daily injections, according to results
BioPharma Dive is testing out a new format rounding up smaller updates from around the industry. Have thoughts on what could make this type of story better? Drop us a
Dive Brief: The Food and Drug Administration on Thursday granted accelerated approval to a new dual-acting drug from Amgen to treat small cell lung cancer in people whose disease has
Four life science investors are pouring $400 million into a new biotechnology startup that’s licensed a portfolio of weight loss medicines from Chinese drugmaker Jiangsu Hengrui Pharmaceuticals, according to a
New data from two late-stage studies of an experimental Bayer drug show it reduced the frequency and severity of common symptoms of menopause, supporting the company’s case for seeking regulatory
San Francisco-based Bolt Biotherapeutics on Tuesday said it is ending development of its lead cancer drug, laying off half its staff and changing up its leadership. Alongside announcing first quarter
One of the developers behind the Alzheimer’s disease drug Leqembi has set new revenue expectations that some analysts see as more practical than previous guidance. On Wednesday, Japan-based Eisai predicted
FogPharma and Artbio, two buzzy biotechnology companies, are betting they can combine their respective technologies to design a new type of radiopharmaceutical drug for cancer. The companies didn’t disclose financial
German pharmaceutical company Bayer eliminated 1,500 roles during the first three months of the year as part of a company makeover CEO Bill Anderson promised last year. Speaking on a
Listen to the article 3 min This audio is auto-generated. Please let us know if you have feedback. Dive Brief: Sanofi is adding to its portfolio of rare disease therapies,
Takeda Pharmaceutical is betting potentially billions of dollars on drugs designed to slow Alzheimer’s disease by harnessing the immune system. Through a deal announced Monday, Takeda has secured an exclusive
Comorbidities are associated with a lack of representation in randomized controlled trials. As a result, it’s often unclear whether trial findings and subsequent treatment recommendations apply to those with comorbidities.
Novo Nordisk is again turning to a Flagship Pioneering startup to find new weight loss drugs, announcing on Thursday a deal with Metaphore Biotechnologies to develop up to two medicines
Dive Brief: Sanofi will pay vaccine maker Novavax $500 million and take a small equity stake in the Maryland-based company as part of a broad COVID-19 shot alliance, the companies announced
Dive Brief: Biotechnology startup Maze Therapeutics has licensed a Pompe disease drug to Shionogi, five months after a challenge from the Federal Trade Commission caused Sanofi to back out of
Moderna on Friday said the Food and Drug Administration has postponed an approval decision on its experimental vaccine for respiratory syncytial virus due to “administrative constraints,” extending a review the
BioPharma Dive is testing out a new format rounding up smaller updates from around the industry. Have thoughts on what could make this type of story better? Drop us a
Dive Brief: Royalty Pharma will pay biotechnology startup ImmuNext $525 million for the right to earn royalties and milestone payments from an autoimmune disease drug the privately held company licensed
Dive Brief: Takeda plans to simplify how its workforce is organized, cut spending and slim down its drug pipeline in a restructuring aimed at improving its profit margin over the
Dive Brief: AstraZeneca will no longer manufacture or supply its COVID-19 vaccine Vaxzevria, announcing Tuesday it is voluntarily withdrawing the shot due to a “decline in demand,” a spokesperson wrote in
Patents reward drugmakers for their inventions and, effectively, the large sums of money they invest in research and development. The legal monopoly that patents provide keeps generic copies at bay
Dive Brief: Verve Therapeutics has treated the first participant in a recently begun clinical trial of the company’s backup gene editing therapy for heart disease, about one month after a
A young boy enrolled in a clinical trial testing an experimental Pfizer gene therapy for Duchenne muscular dystrophy has died, the company revealed Tuesday in a letter posted online by
Physicians at Children’s National Hospital in Washington, D.C., last week collected the stem cells of a young boy with sickle cell disease in preparation for what will be the first
Gossamer Bio has sold rights to an experimental drug that could rival a new medicine from Merck & Co., in a deal at least one analyst believes “bodes well” for
When it comes to data-driven science, your results are only as good as your data and your software. Whether free or premium, your choice of software will greatly impact your
Cancer research is always evolving, as scientists search for ways to combat the tricks tumors use to evade drug therapies. In the last decade alone, immunotherapies, targeted therapies, antibody-drug conjugates
Dive Brief: The gene editing company Metagenomi, which went public earlier this year, said a development partnership struck with Moderna in 2021 has ended after the two companies “mutually agreed”
Dive Brief: An experimental drug from CG Oncology has driven bladder cancers into remission in about three-quarters of people who received it in a Phase 3 trial, matching results the
Mariana Oncology arrived at the J.P. Morgan Healthcare Conference this past January with momentum. The radiopharmaceutical drug developer had secured $175 million in fresh funding four months prior and, in
Dive Brief: Amgen shares soared by double digits Friday following its announcement an obesity drug it’s developing has shown enough promise to warrant advancing into late-stage testing. On an earnings
Dive Brief: Novartis is expanding its pipeline of radiopharmaceutical drugs, announcing Thursday it has agreed to pay $1 billion to acquire biotechnology company Mariana Oncology. Mariana, which specializes in the
Dive Brief: Sales of Novo Nordisk’s obesity drug Wegovy slowed over the first three months of 2024, compared to the fourth quarter last year, as lower realized prices and continued
Pfizer’s rare disease drug Vyndaqel may be its least well known blockbuster medicine. The pharmaceutical company’s COVID-19 vaccine became a household name during the pandemic, while its other top-sellers for
Dive Brief: GSK on Wednesday raised its financial forecasts for the year following strong quarterly sales of its vaccines and HIV medicines. GSK said vaccine sales surged 16% compared to the
Federal officials said a new rule expanding regulatory oversight of laboratory-developed tests will protect patients from inaccurate results while maintaining access to important diagnostics. But some industry experts disagree, arguing
Eli Lilly expects that, by the second half of this year, it will be able to manufacture at least 50% more sellable doses of the main ingredient in its GLP-1
Dive Brief: Prime Medicine will soon begin the first clinical trial of a new drugmaking technique known as prime editing, following the Food and Drug Administration’s clearance of its application
Dive Brief: The Food and Drug Administration on Monday released a final rule strengthening its authority over laboratory developed tests, or LDTs, advancing a policy that has drawn fierce opposition
Sponsors and clinical researchers have been voicing a desire to adopt patient-centric approaches to drug development for more than a decade, but most clinical trials are still designed the same way
Dive Brief: Biogen has seen “encouraging early trends” in the launch of its postpartum depression pill Zurzuvae, revealing in first quarter earnings drug sales that surpassed the estimates of Wall
Dive Brief: Regeneron Pharmaceuticals is upping its investment in genetic medicine, announcing Thursday a $100 million deal with CRISPR drug developer Mammoth Biosciences. Through their collaboration, the companies plan to
Bristol Myers Squibb will cut 6% of its workforce in a restructuring meant to save $1.5 billion in costs by the end of next year. The layoffs will affect some
Dive Brief: The Food and Drug Administration on Friday approved a new gene therapy for hemophilia, clearing Pfizer’s Beqvez for certain people with the less common “B” form of the
Dive Brief: U.S. Humira sales fell 40% year over year during the first three months of 2024, to about $1.8 billion, as biosimilar copycats put pressure on AbbVie’s top-selling drug,
Dive Brief: BioMarin on Wednesday said it’s wrapped up a pipeline review and will stop investing in four experimental therapies because they don’t meet its threshold for patient impact and
AstraZeneca’s revenue and profits grew at a rapid clip over the first three months of the year, beating Wall Street expectations as use of the British drugmaker’s flagship cancer drugs
Investors who had hoped Biogen would do another flashy deal this year may not want to hold their breath, as the biotechnology company signaled that, at least for the time
Moderna is betting big on bespoke artificial intelligence assistants. The biotechnology company on Wednesday said it has expanded a partnership with OpenAI, the buzzy creator of ChatGPT, to give its
Sales of Novartis drugs for heart failure, psoriasis and multiple sclerosis were stronger over the first three months of the year than anticipated, helping the Swiss pharmaceutical company report first
Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick
Dive Brief: Eli Lilly on Monday said it will acquire a drug plant from Nexus Pharmaceuticals to expand its manufacturing capacity for injectable medicines. Located in Pleasant Prairie, Wisconsin, the
Dive Brief: Uwe Schoenbeck, a biotech veteran who most recently was chief scientific officer at Pfizer’s innovation division, has joined Canaan Partners as a venture partner, the investment firm announced
Dive Brief: Alvotech and Teva on Tuesday won Food and Drug Administration approval for Selarsdi, the second biosimilar poised to challenge Johnson & Johnson’s blockbuster psoriasis drug, Stelara. The FDA
Dive Brief: Metsera, a richly funded biotechnology startup, launched Thursday with a portfolio of weight loss drugs the company claims could eventually compete with market-leading medicines from Novo Nordisk and
Cerevel Therapeutics, a biotechnology company in the midst of being acquired by AbbVie, on Thursday said a Parkinson’s disease treatment it’s developing succeeded in a late-stage clinical trial. The treatment,
The Food and Drug Administration has made a medicine from Roche the first specifically available for early treatment of lung tumors driven by a well-known cancer gene. On Thursday, the
Dive Brief: Alvotech and U.S. commercial partner Teva have signed a “long-term agreement” with an unspecified company to boost access to their biosimilar version of AbbVie’s blockbuster drug Humira, Alvotech
Vertex Pharmaceuticals is vying for approval of an experimental and closely watched painkiller that could become an alternative to addictive opioids like Vicodin. On Thursday, the biotechnology company said the
Dive Brief: 23andMe CEO Anne Wojcicki plans to take the DNA testing company private, according to a Wednesday filing with the U.S. Securities and Exchange Commission. Wojcicki currently owns more
An experimental drug designed to improve brain function in people with nerve-degrading disorders has failed a mid-stage study that tested it against Parkinson’s disease. The trial enrolled almost 90 participants,
Fresh clinical trial results for Eli Lilly’s drug Zepbound point to a new use for the weight loss medicine in treating a common sleep disorder, adding to evidence the benefits
An antipsychotic drug from Intra-Cellular Therapies appears to also work as an add-on therapy for depression, according to clinical trial results the New York-based biotechnology company released Tuesday. The large trial
Dive Brief: Sales of Johnson & Johnson’s multiple myeloma medicine Tecvayli more than doubled in the first quarter versus the same period last year, boosting the pharmaceutical company’s oncology business
Shares of Neumora Therapeutics fell Monday after the company disclosed a small clinical trial testing one of its experimental medicines for schizophrenia has been halted by the Food and Drug
Dive Brief: Roche’s new dual-acting blood cancer drug Columvi combined with chemotherapy helped people with a type of lymphoma live longer than people given Rituxan and chemo, the company said
When Katherine Wisner began studying postpartum mental health in the 1980s, the field barely existed. Relatively little research was focused on psychiatric illness related to pregnancy, and postpartum depression wasn’t
Dive Brief: Biotechnology company Rallybio is partnering with Johnson & Johnson, announcing a collaboration Wednesday to develop new treatments for a rare disorder known as fetal and neonatal alloimmune thrombocytopenia,
Dive Brief: Genentech, the research subsidiary of Swiss pharmaceutical giant Roche, has decided to cut short a partnership focused on cell therapies for cancer. Forged in September 2021, the deal
Initial public offerings by biotechnology companies reached pre-pandemic levels during the first quarter, with nine drugmakers collectively raising more than $1.3 billion, according to BioPharma Dive data. The sum is
Dive Brief: Novo Nordisk and Eli Lilly drugs to treat diabetes and obesity have no “causal association” with suicidal thoughts or incidents of suicide or self-harm, Europe’s health regulator said
The U.S. Department of Justice on Wednesday accused Regeneron of defrauding Medicare by knowingly inflating the average sales price for its top-selling eye drug Eylea. In a lawsuit filed in
Dive Brief: Biotechnology company Century Therapeutics is expanding its autoimmune disease research with a pair of deals that will hand it $60 million in new funding and technology from a
Dive Brief: Vertex Pharmaceuticals on Wednesday said it would buy biotechnology company Alpine Immune Sciences and its experimental kidney disease drug for $65 per share, or approximately $4.9 billion in
Dive Brief: Novartis will pause enrollment in certain clinical trials of its breast cancer drug Kisqali in order to meet regulators’ concerns around impurities related to nitrosamines, the company said
Dive Brief: Pfizer on Tuesday said it plans to ask regulators to broaden the approval of its vaccine for respiratory syncytial virus, or RSV, after the shot met the goal
Hoping to repeat a recent success story, the biotechnology startup creator PureTech Health has launched a new company aimed at developing psychiatric medicines. Seaport Therapeutics officially debuted Tuesday with $100
Private funding for biotechnology startups rose during the first three months of the year, suggesting some of the sector’s momentum has translated to stepped-up investment in young drugmakers. Twenty-six companies
Dive Brief: Novo Nordisk’s weight loss drug Wegovy helped people with obesity, diabetes and heart failure have fewer cardiovascular symptoms like fatigue and breathlessness, according to clinical trial results detailed
Dive Brief: Diagonal Therapeutics, a biotechnology startup focused on creating antibodies that activate, rather than block, their targets, emerged from stealth Wednesday with $128 million in funding. Created by industry
Amylyx Pharmaceuticals is pulling from market one of the few approved treatments for ALS. Rarely do drugmakers voluntarily withdraw products. In Amylyx’s case, the decision comes just weeks after a
Dive Brief: Swiss drugmaker Basilea Pharmaceutica on Wednesday won Food and Drug Administration approval for its drug Zevtera in a step that could help address the critical need for new
Johnson & Johnson has agreed to acquire Shockwave Medical for approximately $13.1 billion, the companies announced Friday morning. The deal values Shockwave at $335 per share. J&J said in a
Dive Brief: The Food and Drug Administration has cleared Bristol Myers Squibb and 2seventy Bio’s multiple myeloma cell therapy for earlier use treating the blood cancer, approving the CAR-T medicine
Dive Brief: Boehringer Ingelheim is laying off staff in response to sluggish adoption of its Humira biosimilar Cyltezo, a company spokesperson confirmed to BioPharma Dive. Stat first reported the news Thursday.
Contineum Therapeutics has raised $110 million in an initial public offering, the biotechnology industry’s 10th of the year, to advance a group of drugs it’s developing for neurological and inflammatory
Dive Brief: Merck & Co. has begun a large clinical trial testing an experimental cancer drug it’s developing for tumors that harbor mutations in a tough-to-target gene called KRAS, The
Dive Brief: Genmab said Wednesday it’s agreed to pay $1.8 billion for ProfoundBio, gaining access to the biotechnology startup’s technology for developing antibody-drug conjugates, or ADCs. ProfoundBio’s portfolio includes Rina-S,
Dive Brief: A third biotechnology company from the startup creator Paragon Therapeutics is heading to the public markets. Paragon’s Oruka Therapeutics, which is developing biologic drugs for chronic skin diseases,
Dive Brief: Acorda Therapeutics has filed for bankruptcy and, on Monday, announced it has reached an agreement to sell essentially all its assets to another drugmaker. Acorda said it chose
Dive Brief: An experimental drug being developed by a subsidiary of Roivant Sciences succeeded in a Phase 2 trial testing it for a type of inflammatory eye condition called non-infectious
The year started well for the biotechnology industry. Steady dealmaking coupled with a rebound in initial public offerings helped lift investor confidence and, with it, drugmaker stocks. While that optimism
Dive Brief: Vertex Pharmaceuticals on Monday said it will advance an experimental kidney disease drug into Phase 3 testing and expand enrollment to include adolescents between the ages of 10
The Food and Drug Administration on Tuesday approved a new Merck & Co. drug to treat pulmonary arterial hypertension. Called Winrevair, the drug is the first treatment that targets the
A large clinical trial has found that a drug commonly used by patients with ALS is not effective at treating the nerve-destroying disease. The trial enrolled more than 300 patients
Two years after Art Krieg sold his last biotechnology company to Regeneron Pharmaceuticals, the scientific entrepreneur and industry veteran is quietly building a new drug startup. Called Zola Therapeutics, the
When the Food and Drug Administration expanded approval of Novo Nordisk’s weight loss medicine Wegovy to also protect heart health, the Danish drug giant had already made a pipeline commitment
Dive Brief: Bristol Myers Squibb’s cancer pill Krazati helped people with a certain kind of non-small cell lung cancer live longer without their disease progressing and shrank tumors at a
Dive Brief: Gilead Sciences will pay $30 million and invest another $13.5 million in Xilio Therapeutics to access an experimental immunotherapy drug the Massachusetts biotechnology company is developing for cancer.
Dive Brief: The Food and Drug Administration has approved Akebia Therapeutics’ blood-boosting pill Vafseo for people with anemia from chronic kidney disease, the company said Wednesday, reversing a rejection the agency
Dive Brief: Boundless Bio, a cancer drug developer backed by Bayer and Arch Venture Partners, has raised $100 million in the biotechnology industry’s ninth initial public offering this year. The
Dive Brief: Blackstone Life Sciences will invest as much as $750 million on influenza vaccine research and development by Moderna, announcing Wednesday a private funding deal that gives the private
The Supreme Court on Tuesday heard legal arguments in a high-profile case involving the Food and Drug Administration’s expanded approval of the abortion pill mifepristone, nearly two years after the
Dive Brief: A dual-acting weight loss pill from Viking Therapeutics helped people with obesity lose up to 5% of their body weight over four weeks in a small trial designed
An experimental drug from Axsome Therapeutics was successful in a late-stage clinical trial evaluating it as a treatment for narcolepsy symptoms. The trial found Axsome’s drug to be fast-acting and
Dive Brief: Abbvie is expanding its pipeline of inflammatory disease drugs, announcing Monday a small deal to acquire biotechnology company Landos Biopharma. Per the deal, Abbvie will buy Landos for
Capstan Therapeutics, a biotechnology startup developing medicines that reprogram cells inside the body, has raised another $175 million to bring its first prospect into clinical testing. The high-profile startup, formed
The executives behind autoimmune drug developer Prometheus Biosciences are back, armed with more than $400 million to launch their latest venture, a biotechnology startup known as Mirador Therapeutics. Based in
Listen to the article 3 min This audio is auto-generated. Please let us know if you have feedback. Dive Brief: Bayer CEO Bill Anderson’s structural overhaul is now reaching the
An autoimmune disease drug from Roche and Chugai Pharmaceutical hit its main goal in a closely watched trial, but the results of the study, in a condition called myasthenia gravis,
Listen to the article 3 min This audio is auto-generated. Please let us know if you have feedback. Medicare will cover the costs of Novo Nordisk’s obesity drug Wegovy for
Dive Brief: The Food and Drug Administration on Thursday approved a first-of-its-kind drug for Duchenne muscular dystrophy, clearing Duvyzat, a medicine developed by Italian pharmaceutical company Italfarmaco and to be
Cancer immunotherapy developer NextCure is laying off 37% of its staff and streamlining its research plans, the company said Thursday. Alongside its 2023 earnings, the biotech revealed that it is
Dive Brief: Thermo Fisher Scientific said Wednesday that it has partnered with Bayer to develop companion diagnostic assays for the drugmaker’s precision cancer therapies. Thermo Fisher will develop the next-generation
A young biotechnology company plans to move an experimental medicine for a rare eye disease into late-stage testing after results from a small study signaled that it is generally safe
Dive Brief: Orchard Therapeutics said Wednesday it will offer a new gene therapy to children with a rare, devastating disease at a record-setting wholesale price of $4.25 million. The therapy,
Dive Brief: Bayer on Tuesday said it plans to seek regulatory approval of a drug for symptoms of menopause following positive results from a third Phase 3 trial. The drug,
Dive Brief: Orchard Therapeutics on Monday won Food and Drug Administration approval for the first gene therapy to treat a deadly and devastating rare disease in children called metachromatic leukodystrophy.
Gene therapy developer Bluebird bio has raised a large debt financing in a bid to extend its cash runway for another year. The company on Monday announced that it’s secured
Ask a healthcare professional (HCP), and chances are good that they’d like an easy way to reach out to biopharma field reps. In-person meetings are still the gold standard, but
Dive Brief: Tubulis, a German biotechnology startup developing antibody-drug conjugates, brought in €128 million, or about $140 million, to bring its first prospects into clinical testing. The startup, which is
Asgard Therapeutics has become the latest emerging developer of “in vivo” cell therapies to attract the attention of large drugmakers. The Swedish biotechnology startup on Thursday raised 30 million euros,
Dive Brief: The Biotechnology Innovation Organization on Wednesday backed legislation aiming to limit the industry’s association with Chinese life sciences companies that have alleged ties to the Chinese government, including
Dive Brief: For the first time, the Food and Drug Administration has approved a cell therapy for hard-to-treat forms of two blood cancers. Sold as Breyanzi, the therapy is now
Advisers to the Food and Drug Administration have endorsed the use of two cellular medicines for multiple myeloma earlier in a patient’s disease, overlooking safety concerns raised by agency reviewers
The first drug for metabolic dysfunction-associated steatohepatitis will cost $47,400 per year, its developer, Madrigal Pharmaceuticals, said Thursday. Madrigal revealed the price and launch plan for Rezdiffra on a conference
The Food and Drug Administration has approved the first medicine for a common liver disease that’s been a top target of drugmakers over the last decade. The drug, known as
Dive Brief: AstraZeneca is bolstering its rare disease division with the purchase of Amolyt Pharma, an endocrine disease specialist backed by Novo Holdings. Under the deal announced Thursday, AstraZeneca will
Two cellular medicines for multiple myeloma were associated with an increased risk of early death in clinical testing, raising questions about whether they should be earlier in a patient’s disease,
Dive Brief: IFM Therapeutics, a biotechnology startup developing drugs that target a part of the immune system, said Wednesday Novartis exercised an option to buy its IFM Due subsidiary for
Allogene Therapeutics is turning to gene editing startup Arbor Biotechnologies for help developing “off-the-shelf” cell therapies for autoimmune diseases, the companies said Tuesday. Allogene has been a longtime leader in
Boehringer Ingelheim has formed a partnership with Sosei Heptares in a deal aimed at developing a new type of schizophrenia medicine, the companies announced Monday. Through the partnership, the two
Dive Brief: Roche’s experimental Alzheimer’s disease drug trontinemab showed “best-in-class” potential based on its ability to quickly clear clumps of amyloid protein from the brains of patients enrolled in a